 |
|
Chemotherapy combination outcomes differ for aged, younger colon cancer patients
June 01, 2009ORLANDO, Fla.--The combination of chemotherapies 5FU and oxaliplatin compared to 5FU alone after surgery for colon cancer decreases colon cancer recurrence and promotes longer survival for patients under 70 -- but not for those who are older, according to Mayo Clinic and Dana-Farber Cancer Institute scientists who will present their findings at the American Society of Clinical Oncology's (ASCO) annual meeting in Orlando, Fla.
"By combining information about many patients from a collection of studies, our analysis determined that the more aggressive combination chemotherapy does not benefit older colon cancer patients as it does for those who are younger," said Nadine Jackson McCleary, MD, PhD, Dana-Farber gastrointestinal oncologist and the lead author on the study. Jackson-McCleary is the recipient of a 2008-2009 ASCO Young Investigator's Award.
The data (abstract 4010) will be presented on Saturday, May 30, 3 p.m. ET (Level 2, West Hall D2).
Adding oxaliplatin to chemotherapy treatment with 5FU reduces the risk of recurrence among patients less than 70 years of age who have had their primary cancer removed, the study determined, a finding that was expected based on the results of previous individual trials. Patients under 70 who were treated with 5FU and oxaliplatin had improved disease-free survival, with the addition of oxaliplatin relatively reducing the risk of recurrence or death by approximately 15 percent. Those patients aged 70 and older who were treated with the combined drug therapy, however, did not have improved outcomes compared to patients who received 5FU alone.
"We found that adding chemotherapy agents to the standard 5FU regimen in older patients after surgery did not provide the benefits that younger patients see," Dan Sargent, PhD, Mayo Clinic, a collaborator on the study, agreed. "For the older patient, this means that it is appropriate to choose the better tolerated treatment strategy of 5FU alone."
The benefit of post-surgical treatment for both young and older colon cancer patients with 5FU was documented in a 2001 New England Journal of Medicine study by Sargent and colleagues. By 2003, however, oxaliplatin was approved for use in combination with 5FU because the combination boosted the impact of 5FU on extending disease-free survival after colon cancer surgery. While the combined treatment carried additional risk of side effects, physicians prescribed the treatment strategy to patients of all ages. Initially, studies that examined age-related impact of the aggressive chemotherapy combination did not indicate a difference in survival or recurrence related to patient age.
The current study presented at the ASCO annual meeting includes a large enough patient base to powerfully discern differences related to age that are due to treatment regimen.
"The younger patients do get an additional boost from both drugs used together," Jackson McCleary noted. "Older patients don't benefit from that combination of treatment."
The findings arise from analysis of combined data collected within an expanded database by the Adjuvant Colon Cancer End Points (ACCENT) Group, a consortium of scientists. The ACCENT database includes data from more than 33,500 patients from the United States, Canada, Australia, and Europe. ACCENT is supported by the North Central Cancer Treatment Group (NCCTG); Sargent is chair of ACCENT.
"At this point we can only speculate as to why older patients do not benefit from combined chemotherapies," Jeffrey Meyerhardt, MD, MPH, of Dana-Farber and co-investigator on the trial said. "We do know that a higher number of older patients have to stop the drug before completing the full six month prescribed course of treatment."
"These studies add to the knowledge base that defines how to choose treatment strategies for every individual patient," Sargent said. "Age may become as important a consideration as tumor-specific factors when defining individual medical options for colorectal cancer patients."
Approximately half of all colon cancer patients are older than 70. While about half of the colon cancer patients over 70 will live for five years, those with recurrence typically develop additional tumors within three years. The disease is diagnosed in a million people worldwide every year. In the United States, colorectal cancer accounts for 10 percent of new cancer cases, as well as 10 percent of cancer-related deaths every year.
Dana-Farber Cancer Institute
Adding oxaliplatin to chemotherapy treatment with 5FU reduces the risk of recurrence among patients less than 70 years of age who have had their primary cancer removed, the study determined, a finding that was expected based on the results of previous individual trials. Patients under 70 who were treated with 5FU and oxaliplatin had improved disease-free survival, with the addition of oxaliplatin relatively reducing the risk of recurrence or death by approximately 15 percent. Those patients aged 70 and older who were treated with the combined drug therapy, however, did not have improved outcomes compared to patients who received 5FU alone.
"We found that adding chemotherapy agents to the standard 5FU regimen in older patients after surgery did not provide the benefits that younger patients see," Dan Sargent, PhD, Mayo Clinic, a collaborator on the study, agreed. "For the older patient, this means that it is appropriate to choose the better tolerated treatment strategy of 5FU alone."
The benefit of post-surgical treatment for both young and older colon cancer patients with 5FU was documented in a 2001 New England Journal of Medicine study by Sargent and colleagues. By 2003, however, oxaliplatin was approved for use in combination with 5FU because the combination boosted the impact of 5FU on extending disease-free survival after colon cancer surgery. While the combined treatment carried additional risk of side effects, physicians prescribed the treatment strategy to patients of all ages. Initially, studies that examined age-related impact of the aggressive chemotherapy combination did not indicate a difference in survival or recurrence related to patient age.
The current study presented at the ASCO annual meeting includes a large enough patient base to powerfully discern differences related to age that are due to treatment regimen.
"The younger patients do get an additional boost from both drugs used together," Jackson McCleary noted. "Older patients don't benefit from that combination of treatment."
The findings arise from analysis of combined data collected within an expanded database by the Adjuvant Colon Cancer End Points (ACCENT) Group, a consortium of scientists. The ACCENT database includes data from more than 33,500 patients from the United States, Canada, Australia, and Europe. ACCENT is supported by the North Central Cancer Treatment Group (NCCTG); Sargent is chair of ACCENT.
"At this point we can only speculate as to why older patients do not benefit from combined chemotherapies," Jeffrey Meyerhardt, MD, MPH, of Dana-Farber and co-investigator on the trial said. "We do know that a higher number of older patients have to stop the drug before completing the full six month prescribed course of treatment."
"These studies add to the knowledge base that defines how to choose treatment strategies for every individual patient," Sargent said. "Age may become as important a consideration as tumor-specific factors when defining individual medical options for colorectal cancer patients."
Approximately half of all colon cancer patients are older than 70. While about half of the colon cancer patients over 70 will live for five years, those with recurrence typically develop additional tumors within three years. The disease is diagnosed in a million people worldwide every year. In the United States, colorectal cancer accounts for 10 percent of new cancer cases, as well as 10 percent of cancer-related deaths every year.
Dana-Farber Cancer Institute
Colon Cancer Current Events and Colon Cancer News RSSCurry-cure? Spicing up the effectiveness of a potential disease-fighter
Scientists are reporting development of a nano-size capsule that boosts the body's uptake of curcumin, an ingredient in yellow curry now being evaluated in clinical trials for treatment of several diseases.
Colon cancer screening more effective earlier in day, UCLA study finds
The effectiveness of a screening colonoscopy may depend on the time of day it is performed. According to a new UCLA study, early-morning colonoscopies yielded more polyps per patient than later screenings, and fewer polyps were found hour by hour as the day progressed.
Study shows hormone replacement therapy decreases mortality in younger postmenopausal woman
Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women.
Experts issue call to reconsider screening for breast cancer and prostate cancer
Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association."
Metals could forge new cancer drug
Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.
New data: Hospital imaging centers poised to pull back, hitting patients hardest in rural areas
Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation.
Whole-brain radiotherapy after surgery or radiosurgery not recommended for brain metastases
Whole-brain radiotherapy should not be given routinely to all patients whose cancer has spread to the brain, say researchers who found that using it after surgery or radiosurgery in patients with a limited number of brain metastases and stable cancer in the rest of the body did not extend lives or help patients remain functionally independent for longer.
New blood tests promise simple, cost-effective diagnosis of gastrointestinal cancers
Promising results from two new blood tests that can aid in the early identification of patients with gastrointestinal (GI) cancers will be presented at Europe's largest cancer congress.
GEN reports on expanding NextGen sequencing applications
Next-Generation Sequencing (NGS) technologies are not only beginning to supplant traditional Sanger sequencing methodology but are also giving DNA microarrays a run for the money as well, reports Genetic Engineering & Biotechnology News (GEN).
Natural compounds, chemotherapeutic drugs may become partners in cancer therapy
Research in the Linus Pauling Institute at Oregon State University suggests that some natural food compounds, which previously have been studied for their ability to prevent cancer, may be able to play a more significant role in treating it - working side-by-side with the conventional drugs that are now used in chemotherapy.
More Colon Cancer Current Events and Colon Cancer News Articles
 |
American Cancer Society's Complete Guide to Colorectal Cancer by American Cancer Society (Author) Don't die of embarrassment--get informed about colorectal cancer Although colorectal cancer is the third most common cancer found in men and women, you may be unaware of your risk and don't know what you can do to prevent this serious disease. You may be too embarrassed to ask your doctor about changes in your bowel habits or get screened for colorectal cancer. American Cancer Society's Complete Guide to Colorectal Cancer provides sound information and support if you are concerned about or diagnosed with colorectal cancer. Written by experts in oncology, nursing, research, and colorectal cancer care, the up-to-date, evidence-based text explores every aspect of colorectal cancer, from physical to emotional aspects of the disease, including: What colorectal... |
 |
The Colon Cancer Survivors' Guide, Second Edition: Living Stronger, Longer by Curtis Pesmen (Author) Based on an award-winning series of Esquire magazine articles on his battle with colon cancer, Pesmen shows how a person stops becomng a patient and starts becoming a survivor. Incluses a chorus of survivors' voices, and casts light on the physical, emotional and psychological needs of those striving to move forward confidently with their lives. New, revised second edition updates treatments and adds new survivors' voices and surveys treatments on the horizon. |
 |
Living With Colon Cancer: Beating the Odds by Eliza Wood Livingston (Author), David, M.D. Spiegel (Foreword) Despite the efforts of Katie Couric to draw attention to the importance of colonoscopy screening for the detection of colon cancer, this cancer still does not receive the publicity devoted to breast, lung, and prostate cancer. Yet colorectal cancer is the third most common malignancy in the world and is the second leading cause of death from cancer next to lung cancer. As a result, colon cancer patients and their families often feel isolated and do not have the support and information networks available to those coping with more publicized illnesses. In this helpful and inspiring book, Eliza Wood Livingston provides a wealth of practical information about colon cancer while telling of her own heroic battle against this challenging disease and her survival after a bleak diagnosis.... |
 |
Colon Cancer Answers by Dr. Bruce A. Feinberg (Author), Richard J. Lenz (Editor), Imagineering (Editor) One of the greatest failures of public health practices and policy in America is the mismanagement of colon cancer. Despite the fact that colon cancer is 90 percent preventable through safe, accessible, cost-effective screening tests, this terrible disease remains the second leading cause of cancer death. Each year, more than 150,000 Americans will die -- an unnecessary and costly human tragedy. Despite the scale of the colon cancer crisis, there are few up-to-date resources available for the newly diagnosed and their loving family and friends. Although this book was conceived as a primer for those dealing directly or indirectly with colon cancer, it is Dr. Feinberg's fervent hope that it will also increase awareness of the preventable nature of this devastating disease. |
 |
Positive Options for Colorectal Cancer: Self-Help and Treatment by Carol Ann Larson (Author), Kathleen Ogle (Foreword) Colorectal cancer develops slowly over a period of several years, undetected, usually as polyps. It is a preventable and treatable disease if caught in time, yet most know little about how to read its symptoms. Written for the layperson, this book covers all the uncomfortable questions and answers about the disease, from prevention and warning signs, to screening and diagnosis techniques, to making decisions and developing treatment plans. Also included are positive stories about life after cancer by 12 survivors. |
 |
Be a Survivor: Colorectal Cancer Treatment Guide by Vladimir Lange (Author) Dr. Lange’s comprehensive overview of cancer and treatment options offers detailed information using simple, concise language and a wide variety of color photos and drawings. Colorectal cancer patients need to know more about their disease, yet there is an overload of information. Be a Survivor gives the patient the specific, reliable and necessary information to make good decisions about their cancer and treatment options. Annually, 150,000 Americans are told they have colorectal cancer, making it one of the top three most common cancers in the United States. Diagnosed early, colorectal cancer is treatable, often curable, and vey preventable. This resource covers all aspects of colorectal cancer—from diagnosis to recovery, including a chapter for the patient's spouse. |
 |
What Your Doctor May Not Tell You About(TM) Colorectal Cancer: New Tests, New Treatments, New Hope (What Your Doctor May Not Tell You About...) by Mark Bennett Pochapin (Author) - What Your Doctor May Not Tell You About Colorectal Cancer was published in Warner hardcover (0-446-53188-X) in 3/04. The book features a foreword by Katie Couric. - Dr. Pochapin made an appearance on the Today show in conjunction with the hardcover publication of this book. Previously, he had been chosen by Katie Couric to be the Medical Director of the Jay Monahan Center for Gastrointestinal Health, named in honor of Ms. Couric's late husband. - The author is an associate professor of clinical medicine at the Weill Medical College of Cornell University and Chief of Gastrointestinal Endoscopy at New York Presbyterian Hospital's Weill Cornell Medical Center. - There are approximately 100,000 new colorectal cancer cases diagnosed annually, making it the second leading cause of... |
 |
Understanding Colon Cancer by A. Richard, M.D., F.A.C.P. Adrouny (Author) Stanford Univ., CA. Pocket-sized consumer text provides concise information about the disease. Reviews high-risk conditions, genetics, warning signs, screening, diagnosis, stages of the disease, virtual colonoscopy and treatment. Softcover, hardcover available. DNLM: Colonic Neoplasms--prevention & control. |
 |
Tell Me What to Eat to Help Prevent Colon Cancer by Elaine Magee (Author) Elaine Magee gives you all the information you can never seem to understand when the doctor rattles it off, and she answers all the questions you ever wanted to ask a dietitian about preventing colon cancer. You will find a host of specific recommendations-what to eat, what to avoid, and how to incorporate these changes into your lifestyle. Tell Me What to Eat to Help Prevent Colon Cancer begins with an overview of colon cancer in all its forms. Readers get a detailed yet completely understandable explanation of how the cancer begins and how it spreads-an explanation that is based on the latest medical information. Readers gain a better understanding of what colon cancer is and what actions they can take now to help prevent it. Also included are dozens of healthful, practical,... |
 |
It's Half Past Midnight: A Poignant, Practical and Humorous Trip Through My Colon by Robert E. Cull (Author) Robert Emerson Cull's It's Half Past Midnight: A Poignant, Practical and Humorous Trip Through My Colon is a poignant and inspiring account of the author's battle with colon cancer, and the tremendous healing power of a an attitude of gratefulness and good fortune. Filled with insight and humor, this book would be of great value to anyone facing health issues, or any other of life's challenges. |
| © 2009 BrightSurf.com |